Karin J. Blakemore

Last updated

Karin J. Blakemore (born 1953) is a leading medical geneticist and works in gynecology and obstetrics, human genetics, and maternal and fetal medicine. Dr. Blakemore's major contribution to medicine stems from her research as a member of a team that aimed to fight genetic disorders through the in utero transplantation of donor cells using a mouse as an animal model. Through this initial research in regards to first trimester prenatal diagnosis, Blakemore initiated the beginning of research on in utero bone marrow transplantation for genetic disorders of the fetus.

Contents

Education

Karin Blakemore began her education by earning her B.A. degree from the University of Pennsylvania. She went on to earn her M.D. degree from the Medical College of Ohio at Toledo in 1978. After medical school, Dr. Blakemore completed her residency at the New York University Medical Center with a concentration in obstetrics and gynecology. Blakemore went on to pursue a postdoctoral fellowship at Yale University School of Medicine in human genetics and later pursued another postdoctoral fellowship through the Washington University School of Medicine in St. Louis in maternal-fetal medicine. [1] [2]

Career

In 1987 Dr. Blakemore joined Johns Hopkins School of Medicine where she was appointed to the position of director of chorionic villus sampling program and laboratory and director of alphafetoprotein (AFP) referral service. After five years in her positions, Blakemore took on the position of director of the prenatal diagnostic center in 1992 and in 1994 was appointed to the position of the director of maternal-fetal medicine and that division's fellowship program.

Dr. Blakemore's team at the Johns Hopkins University's Institute of Genetic Medicine worked to determine the ideal number of cells to use in human in utero transplantation by utilizing a human-mouse model. Implanting human donor cells into the human-mouse model allowed the team to predict both the lower and upper extremes of outcome that occur during transplants. As a result of Blakemore's team's research it is a possibility that in utero transplants for a variety of congenital disorders may be developed.

Blakemore has three board certifications through the American Board of Medical Genetics, Obstetrics and Gynecology, and Maternal-Fetal Medicine. In addition to her medical career, Blakemore has joined the faculty of Johns Hopkins School of Medicine as an associate professor in oncology, obstetrics, and gynecology, and the Johns Hopkins Bloomberg School of Public Health in population and family health sciences. [1] [2]

Honors

Dr. Blakemore was recommended to "Best Doctors in America" by her peers and was recognized by the Society of Perinatal Obstetricians with their Award for Best Genetic Research in the field of Perinatal Medicine. [1] [2]

Related Research Articles

<span class="mw-page-title-main">Amniocentesis</span> Sampling of amniotic fluid done mainly to detect fetal chromosomal abnormalities

Amniocentesis is a medical procedure used primarily in the prenatal diagnosis of genetic conditions. It has other uses such as in the assessment of infection and fetal lung maturity. Prenatal diagnostic testing, which includes amniocentesis, is necessary to conclusively diagnose the majority of genetic disorders, with amniocentesis being the gold-standard procedure after 15 weeks’ gestation.

Genetic counseling is the process of investigating individuals and families affected by or at risk of genetic disorders to help them understand and adapt to the medical, psychological and familial implications of genetic contributions to disease; this field is considered necessary for the implementation of genomic medicine. The process integrates:

Prenatal testing consists of prenatal screening and prenatal diagnosis, which are aspects of prenatal care that focus on detecting problems with the pregnancy as early as possible. These may be anatomic and physiologic problems with the health of the zygote, embryo, or fetus, either before gestation even starts or as early in gestation as practicable. Screening can detect problems such as neural tube defects, chromosome abnormalities, and gene mutations that would lead to genetic disorders and birth defects, such as spina bifida, cleft palate, Down syndrome, Tay–Sachs disease, sickle cell anemia, thalassemia, cystic fibrosis, muscular dystrophy, and fragile X syndrome. Some tests are designed to discover problems which primarily affect the health of the mother, such as PAPP-A to detect pre-eclampsia or glucose tolerance tests to diagnose gestational diabetes. Screening can also detect anatomical defects such as hydrocephalus, anencephaly, heart defects, and amniotic band syndrome.

Prenatal development includes the development of the embryo and of the fetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.

Agenesis of the corpus callosum (ACC) is a rare birth defect in which there is a complete or partial absence of the corpus callosum. It occurs when the development of the corpus callosum, the band of white matter connecting the two hemispheres in the brain, in the embryo is disrupted. The result of this is that the fibers that would otherwise form the corpus callosum are instead longitudinally oriented along the ipsilateral ventricular wall and form structures called Probst bundles.

The Burlo Garofolo Pediatric Institute is a children's hospital located in Trieste, Italy.

Frank A. Chervenak, MD currently serves as Chair of Obstetrics and Gynecology, Lenox Hill Hospital; Chair of Obstetrics and Gynecology and Associate Dean of International Medicine, Zucker School of Medicine at Hofstra/Northwell.

<span class="mw-page-title-main">Intrauterine hypoxia</span> Medical condition

Intrauterine hypoxia occurs when the fetus is deprived of an adequate supply of oxygen. It may be due to a variety of reasons such as prolapse or occlusion of the umbilical cord, placental infarction, maternal diabetes and maternal smoking. Intrauterine growth restriction may cause or be the result of hypoxia. Intrauterine hypoxia can cause cellular damage that occurs within the central nervous system. This results in an increased mortality rate, including an increased risk of sudden infant death syndrome (SIDS). Oxygen deprivation in the fetus and neonate have been implicated as either a primary or as a contributing risk factor in numerous neurological and neuropsychiatric disorders such as epilepsy, attention deficit hyperactivity disorder, eating disorders and cerebral palsy.

<span class="mw-page-title-main">Fetal surgery</span> Growing branch of maternal-fetal medicine

Fetal surgery also known as antenatal surgery, prenatal surgery, is a growing branch of maternal-fetal medicine that covers any of a broad range of surgical techniques that are used to treat congenital abnormalities in fetuses who are still in the pregnant uterus. There are three main types: open fetal surgery, which involves completely opening the uterus to operate on the fetus; minimally invasive fetoscopic surgery, which uses small incisions and is guided by fetoscopy and sonography; and percutaneous fetal therapy, which involves placing a catheter under continuous ultrasound guidance.

<span class="mw-page-title-main">Kypros Nicolaides</span>

Kyprianos "Kypros" Nicolaides is a Greek Cypriot-born British Professor in Fetal Medicine at King's College Hospital, London. He is one of the pioneers of fetal medicine and his discoveries have revolutionised the field. He was elected to the US National Academy of Medicine in 2020 for 'improving the care of pregnant women worldwide with pioneering rigorous and creative approaches, and making seminal contributions to prenatal diagnosis and every major obstetrical disorder'. This is considered to be one of the highest honours in the fields of health and medicine and recognises individuals who have demonstrated outstanding professional achievement and commitment to service.

<span class="mw-page-title-main">Maternal–fetal medicine</span> Branch of medicine

Maternal–fetal medicine (MFM), also known as perinatology, is a branch of medicine that focuses on managing health concerns of the mother and fetus prior to, during, and shortly after pregnancy.

Joseph Daniel Schulman is a physician, medical researcher, and biomedical entrepreneur in the fields of genetic diseases and human reproduction.

The following outline is provided as an overview of and topical guide to obstetrics:

Nebojsa V. Radunovic is a university professor of obstetrics and gynecology at University of Belgrade's School of Medicine* Reference 1, Chair of Human reproduction department at Institute for Obstetrics and Gynecology, Clinical Center of Serbia and a corresponding member of the Serbian Academy of Sciences and Arts. He was born in 1954 in Kosovska Mitrovica, Kosovo, then SFRY.

Cell-free fetal DNA (cffDNA) is fetal DNA that circulates freely in the maternal blood. Maternal blood is sampled by venipuncture. Analysis of cffDNA is a method of non-invasive prenatal diagnosis frequently ordered for pregnant women of advanced maternal age. Two hours after delivery, cffDNA is no longer detectable in maternal blood.

<span class="mw-page-title-main">Diana W. Bianchi</span> American medical geneticist and neonatologist

Diana W. Bianchi is an American medical geneticist and neonatologist noted for her research on fetal cell microchimerism and prenatal testing. She is the director of the Eunice Kennedy ShriverNational Institute of Child Health and Human Development, part of the National Institutes of Health. Bianchi had previously been the Natalie V. Zucker Professor of Pediatrics, Obstetrics, and Gynecology at Tufts University School of Medicine and executive director of the Mother Infant Research Institute at Tufts Medical Center. She also has served as Vice Chair for Research in the Department of Pediatrics at the Floating Hospital for Children at Tufts Medical Center.

Alice Benjamin is a Canadian specialist in fetal and maternal medicine.

<span class="mw-page-title-main">Ritsuko Pooh</span> Japanese obstetrician and gynecologist

Rituko Kimata Pooh is a Japanese obstetrician and gynecologist.

Noninvasive prenatal testing is a method used to determine the risk for the fetus being born with certain chromosomal abnormalities, such as trisomy 21, trisomy 18 and trisomy 13. This testing analyzes small DNA fragments that circulate in the blood of a pregnant woman. Unlike most DNA found in the nucleus of a cell, these fragments are not found within the cells, instead they are free-floating, and so are called cell free fetal DNA (cffDNA). These fragments usually contain less than 200 DNA building blocks and arise when cells die, and their contents, including DNA, are released into the bloodstream. cffDNA derives from placental cells and is usually identical to fetal DNA. Analysis of cffDNA from placenta provides the opportunity for early detection of certain chromosomal abnormalities without harming the fetus.

Beryl Rice Benacerraf was an American radiologist and professor of obstetrics, gynecology and reproductive biology and radiology at Harvard Medical School. She was a pioneer in the use of prenatal ultrasound to diagnose fetal abnormalities, including Down syndrome. In 2021, she was recognized as a "Giant in Obstetrics and Gynecology" by the American Journal of Obstetrics & Gynecology.

References

  1. 1 2 3 "Dr. Karin J. Blakemore". www.nlm.nih.gov. National Library of Medicine. Retrieved 8 November 2014.
  2. 1 2 3 "Karin J Blakemore, MD". www.hopkinsmedicine.org. Johns Hopkins University. Retrieved 8 November 2014.